Applied BioCode (TW:6598) — Market Cap & Net Worth
Market Cap & Net Worth: Applied BioCode (6598)
Applied BioCode (TW:6598) has a market capitalization of $97.49 Million (NT$3.09 Billion) as of August 3, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #19208 globally and #1068 in its home market, demonstrating a 6.17% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Applied BioCode's stock price NT$30.10 by its total outstanding shares 102801000 (102.80 Million). See capital reinvestment ratio of Applied BioCode to understand how much of operating cash flow is reinvested back into capital assets.
Applied BioCode Market Cap History: 2017 to 2026
Applied BioCode's market capitalization history from 2017 to 2026. Data shows change from $124.66 Million to $97.49 Million (-8.22% CAGR).
Applied BioCode Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Applied BioCode's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.19x
Applied BioCode's market cap is 0.19 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $124.66 Million | $26.76 Million | -$263.46 Million | 4.66x | N/A |
| 2018 | $125.44 Million | $37.15 Million | -$268.31 Million | 3.38x | N/A |
| 2019 | $124.05 Million | $104.69 Million | -$280.07 Million | 1.18x | N/A |
| 2020 | $190.44 Million | $299.01 Million | -$103.50 Million | 0.64x | N/A |
| 2021 | $139.27 Million | $319.96 Million | -$165.20 Million | 0.44x | N/A |
| 2022 | $100.40 Million | $390.30 Million | -$184.73 Million | 0.26x | N/A |
| 2023 | $81.94 Million | $395.17 Million | -$164.20 Million | 0.21x | N/A |
| 2024 | $65.26 Million | $343.07 Million | -$260.81 Million | 0.19x | N/A |
Competitor Companies of 6598 by Market Capitalization
Companies near Applied BioCode in the global market cap rankings as of August 3, 2026.
Key companies related to Applied BioCode by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #114 globally with a market cap of $183.80 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #189 globally with a market cap of $124.64 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #233 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #238 globally with a market cap of $103.60 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #114 | Abbott Laboratories | NYSE:ABT | $183.80 Billion | $105.70 |
| #189 | Stryker Corporation | NYSE:SYK | $124.64 Billion | $325.70 |
| #233 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #238 | Medtronic PLC | NYSE:MDT | $103.60 Billion | $85.39 |
Applied BioCode Historical Marketcap From 2017 to 2026
Between 2017 and today, Applied BioCode's market cap moved from $124.66 Million to $ 97.49 Million, with a yearly change of -8.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$97.49 Million | +36.82% |
| 2025 | NT$71.25 Million | +9.18% |
| 2024 | NT$65.26 Million | -20.36% |
| 2023 | NT$81.94 Million | -18.39% |
| 2022 | NT$100.40 Million | -27.91% |
| 2021 | NT$139.27 Million | -26.87% |
| 2020 | NT$190.44 Million | +53.52% |
| 2019 | NT$124.05 Million | -1.11% |
| 2018 | NT$125.44 Million | +0.63% |
| 2017 | NT$124.66 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Applied BioCode was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $97.49 Million USD |
| MoneyControl | $97.49 Million USD |
| MarketWatch | $97.49 Million USD |
| marketcap.company | $97.49 Million USD |
| Reuters | $97.49 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Applied BioCode
Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. Its products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the detection steps, PCR amplification, and hybridization and target capture; and the BioCode 2500 analyzer, a system that reads each barcode and quantifies the BMB target us… Read more